Showing results (81-90 of 146) with videos related to

Sort By:
Pageof 15
Cancer|December 20, 2002
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignanciesTarek Mekhail, Thomas E Hutson, Paul Elson, et al.
The Journal of Craniofacial Surgery|September 7, 2010
Sinus pericranii--"Don't judge a lump by its surface"Amit K Shah, Andrew C Camilleri, Peter Kirkpatrick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effectsThomas E Hutson, Luis Molto, Tarek Mekhail, et al.
Investigational New Drugs|August 11, 2010
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumorsAndrea Wang-Gillam, Susanne M Arnold, Ronald M Bukowski, et al.
Anticancer Research|August 8, 2009
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independentSusan A J Vaziri, Dale R Grabowski, Jason Hill, et al.
Urologic Oncology|January 9, 2007
Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicityEna Segota, Tarek Mekhail, Thomas Olencki, et al.
Cancer Research|August 9, 2003
Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinomaTomohide Tatsumi, Christopher J Herrem, Walter C Olson, et al.
Cancer|January 8, 2009
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancerDaniel Y C Heng, Kim N Chi, Nevin Murray, et al.
Anticancer Research|December 12, 2003
c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosisSusan A Vaziri, Dale R Grabowski, Masahiro Tabata, et al.
Cancer|September 1, 2010
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumabJorge A Garcia, Thomas E Hutson, Paul Elson, et al.
Pageof 15